Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18161771 | 1.00 | L3MBTL1 (0.36) | L3MBTL1NPC1ALDH1A1GLAGAA | |
| SCHEMBL20462855 | 0.82 | HPGD (0.33) | L3MBTL1HPGDALOX15 | |
| SCHEMBL18161775 | 0.82 | HPGD (0.33) | L3MBTL1HPGDALOX15 | |
| SCHEMBL20462837 | 0.78 | CYP2D6 (0.34) | L3MBTL1ALDH1A1GAATSHRMAPK1 | |
| SCHEMBL18161758 | 0.78 | CYP2D6 (0.34) | L3MBTL1ALDH1A1GAATSHRMAPK1 | |
| SCHEMBL18161772 | 0.78 | MAPT (0.45) | L3MBTL1NPC1ALDH1A1GAAALOX15 | |
| SCHEMBL20143467 | 0.78 | MAPT (0.45) | L3MBTL1NPC1ALDH1A1GAAALOX15 | |
| SCHEMBL18161785 | 0.73 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL20462849 | 0.73 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL14163513 | 0.73 | L3MBTL1 (0.49) | L3MBTL1NPC1ALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180223042-A1 | Method of Preparing Poly(Alkylene Carbonate) via Copolymerization of Carbon Dioxide/Epoxide in the Presence of Novel Complex | SK INNOVATION CO., LTD. (KR) | 2018-08-09 | — | — | US | disclosed |
| US-9969842-B2 | Method of preparing poly(alkylene carbonate) via copolymerization of carbon dioxide/epoxide in the presence of novel complex | SK INNOVATION CO., LTD. (KR) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180223042-A1 | Method of Preparing Poly(Alkylene Carbonate) via Copolymerization of Carbon Dioxide/Epoxide in the Presence of Novel Complex | SMARCC2, SMARCC1, CLNS1A | L3MBTL1 4884/4885NPC1 4709/4885ALDH1A1 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.